Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab for acute Charcot foot in patients with diabetes
NL-OMON59013Phase 3Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Sep 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of denosumab in Charcot neuroarthropathy (CN), sponsored by Amsterdam University Medical Center. Primary endpoints: Time to cession of total contact cast and Curation of foot fractures on imaging. Started Sep 2017; status: completed.
02
Drugs
denosumab
03
Conditions
Charcot neuroarthropathy (CN)
Beyond the preview
Go deeper on NL-OMON59013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59013.